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Introduction
 Carcinoma of the urinary bladder is a common cancer 
that accounts for approximately 300,000 new cases each 
year (Jemal et al., 2008). In the majority of patients 
the diagnosis is performed at early stages and treated 
with endoscopic and intravesical treatments. However, 
approximately 80% of patients recur in 1 to 2 years 
and despite radical cystectomy and systemic therapy, a 
substantial proportion of cases progress to invasive tumors 
and die from metastasis within 12-15 months (Kaufman, 
2006).
 In the last decade, efforts have been made in order 
identify clinically relevant biomarkers to assist tumor 
grading, prognosis, and prediction of treatment response. 
The abnormal activation of the PI3K⁄Akt⁄mTOR pathway 
has been repeatedly implicated in the development and 
maintenance of many human tumors, including urothelial 
carcinoma (Qian et al., 2009; Ching et al., 2010). The 
phosphatidylinositol 3-kinase PI3K is an essential enzyme 
in signal transduction from various stimuli to downstream 
pathways involved in diverse responses associated with 
growth, proliferation and survival. Activated PI3K 
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Abstract
 Bladder cancer is a common malignancy worldwide. Despite the increased use of cisplatin-based combination 
therapy, the outcomes for patients with advanced disease remain poor. Recently, altered activation of the PI3K/
Akt/mTOR pathway has been associated with reduced patient survival and advanced stage of bladder cancer, 
making its upstream or downstream components attractive targets for therapeutic intervention. In the present 
study, we showed that treatment with DTCM-glutaramide, a piperidine that targets PDK1, results in reduced 
proliferation, diminished cell migration and G1 arrest in 5637 and T24 bladder carcinoma cells. Conversely, no 
apoptosis, necrosis or autophagy were detected after treatment, suggesting that reduced cell numbers in vitro are 
a result of diminished proliferation rather than cell death. Furthermore previous exposure to 10 µg/ml DTCM-
glutarimide sensitized both cell lines to ionizing radiation. Although more studies are needed to corroborate 
our findings, our results indicate that PDK1 may be useful as a therapeutic target to prevent progression and 
abnormal tissue dissemination of urothelial carcinomas. 
Keywords: Urothelial cancer - PI3K/Akt/mTOR pathway - molecular target - therapy
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generates phosphatidylinositol-3,4,5-triphosphate, which 
recruits phosphatidylinositol-dependent kinase 1 (PDK1) 
and Akt serine/threonine kinase at the plasma membrane, 
resulting in activation of Akt which in turn activates 
multiple downstream targets, including the mammalian 
target of rapamycin mTOR (Cully et al., 2006). Altered 
mTOR pathway activity is associated with reduced patient 
survival and advanced stage in bladder carcinoma (Hansel 
et al., 2010; Sun et al., 2011), therefore, the PDK1/
Akt pathway is believed to be an attractive target for 
therapeutic intervention.
 Here, we present evidence of the antiproliferative 
effects of the piperidine compound DTCM-glutarimide on 
5637 and T24 cells offering a rationale for a therapeutic 
targeting in bladder cancer.
Materials and Methods
Cell Culture 
 The established bladder carcinoma cell lines 5637 
(moderately differentiated tumour) and T24 (high-grade 
tumour) were obtained from the Cell Bank of the Federal 
University of Rio de Janeiro, Brazil. Cells were cultured 
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in HAM F10 (T24) and RPMI 1640 (5637) (GibcoBRL, 
Life Technologies®, Carlsbad, CA, USA) supplemented 
with 10% fetal bovine serum, penicillin (100U/mL) and 
streptomycin (100ug/mL) at 37°C in a humidified 5% CO2 
incubator.
Drug and treatments 
 DTCM-glutarimide (3-[(dodecylthiocarbonyl)
methyl]glutarimide) was synthesized as described earlier 
(Ishikawa et al., 2009).  In one hand, this drug was designed 
and synthesized as a derivative of 9-methylstreptimidone 
that inhibits NF-kB (Wang et al., 2006). However, 
DTCM-gltarimide did not directly inhibit NF-kB. Rather, 
it exerted anti-inflammatory action by inhibiting AP-1 
activity (Takeiri et al., 2011), while, new evidence has 
demonstrated its anti-tumoral effects by inhibiting PDK1 
(Ito et al., 2011). For all experiments, cells were treated 
with 2.5, 5, 10 and 20 µg/ml. Corresponding control 
cultures received an equal volume of solvent.
Measurement of cell growth 
 Cell survival was assessed using the XTT assay (XTT 
II; Roche Molecular Biochemicals, Indianapolis, IN). 
Briefly, equal amounts of cells were seeded in 96-well 
flat-bottom plates (2,500 cells/well) and allowed to attach 
to the incubator and proliferate for 24h. Subsequently, cells 
were treated with different concentrations of DTCM-g 
(2.5, 5, 10 and 20 µg/ml) and incubated for 24, 48 and 
72h. After treatment, the culture medium was removed 
and replaced with medium containing 10 μL of XTT dye 
(3 mg/mL) in each well. The plates were incubated for 2 
hours at 37°C and the formazan product was measured 
at 455 and 650 nm by using an iMarkmicroplate reader 
(Bio-Rad Laboratories®). For growth analyses, trypan blue 
exclusion and cell counting were also implemented. Each 
experiment was performed in triplicate wells and repeated 
in three sets of tests. 
Colony Formation Assay
 Clonogenic assays were performed according to 
Franken et al. (2006). After tripsinization, single cell 
suspensions of 300 cells were seeded in 6-well plates 
and treated with DTCM-g 2.5, 5, 10 and 20 µg/ml 
concentrations for 24h. Following that period, the culture 
medium was removed and replaced with drug-free 
medium. The cell cultures were incubated for 10 days 
and then the colonies were rinsed with PBS, fixed with 
methanol and stained with Giemsa. Only colonies with > 
50 cells were counted. Assays were performed in triplicate.
Cell cycle analysis
 In each time point after drug treatment, the cells were 
detached using trypsin-EDTA, fixed in 70% ethanol, 
stained with propidium iodide, and analysed on a Guava 
Personal Cell Analysis system (Guava Technologies, 
Hayward, CA, USA) according to the standard protocol 
provided by the manufacturer. 
 Percentages of cells in G0/G1, S, or G2/M phase were 
collected and processed using the GUAVA Cytosoft 4.2.1 
version Software. All cell cycle analyses were performed 
in triplicate.
Analysis of caspase activation
 For apoptosis 3x104 cells were seeded on 6-well plates 
containing 3 ml of culture medium. After 24 hours, the 
medium was replaced and cells treated with the different 
concentrations of DTCM-g or vehicle only and cultured 
for additional 48h. Caspase activation was determined 
using the NucView™ 488 Caspase-3 Detection in Living 
Cells kit (Biotium Inc. Hayward, CA, USA) according to 
the manufacturer’s instructions. Concisely, treated cells 
were trypsinized and incubated for 40 minutes at room 
temperature with the capase-3 substrate. After that period, 
cells were fixed in formaldehyde and counterstained with 
4’,6-diamidino-2-phenylindole (DAPI). Then, samples 
were mounted, coverslipped and analysed by fluorescence 
microscopy with a triple filter. Five hundred nuclei 
were analysed per treatment and cells were scored and 
categorized according to differential staining.
Detection of necrotic cells by differential staining
 Necrotic cells were recognized by differential staining 
according to Lee and Shacter (1999). Treated cells were 
trypsinized, centrifuged and incubated for 5 min at 37°C 
with bisbenzimide (Hoechst 33342), propidium iodide 
and fluorescein diacetate (Sigma Chemical Co., St. 
Louis, USA). Then, samples were mounted, coverslipped 
and analysed by fluorescence microscopy with a triple 
filter. Cells were scored and categorized as follows: (1) 
normal: blue nucleus and green cytoplasm, (2) apoptotic: 
fragmented blue nucleus and green cytoplasm and (3) 
necrotic: red nucleus. Five hundred nuclei were analysed 
per treatment.
Detection and quantification of autophagy by acridine 
orange staining
 One of the most frequently used methods for following 
the autophagic process is staining with acidotropic dyes 
such as acridine orange (AO) (Klionsky et al., 2008). In 
AO-stained cells, the cytoplasm and nucleolus fluoresce 
bright green, whereas acidic autophagic vacuoles 
(autophagosomes) fluoresce bright red. After different 
treatments for 48h, cells were stained with AO at a final 
concentration of 1 μg/ml for 15 minutes, removed from 
the plate and collected in phenol red-free growth medium. 
Green and red fluorescence emission were measured 
with flow cytometry and the data were analyzed with the 
GUAVA Cytosoft 4.2.1 version Software. 
In vitro scratch assay for analysis of cell migration
 In vitro scratch assays to quantify tumour migration 
rates were performed according to Liang et al. (2007) 
with slight modifications. Briefly cells were grown to 
confluence on 12 well plates and scratch wounds were 
then created using a pipet tip (200µl) and the wound 
site photographed digitally at time zero. Cells were 
then treated with different concentrations of DTCM-g 
and subcultured for 24hs in medium supplemented with 
only 1% fetal bovine serum. After that period, cells were 
photographed and the Motic Images Plus v2.0 software 
(Motic China Group Co., Ltd) was used to calculate the 
cell-free area. Cell migration rate was calculated as the 
distance (nanometers) travelled by cells over time.
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Figure 1. Characterization of the Effects of PDK1 Inhibition on Cell Growth and Clonogenic Survival in 5637 
and T24 Cells Treated with DTCM-g.  A) Growth inhibition in 5637 and T24 cell lines treated with DTCM-g at the indicated 
concentrations for 24h, 48h and 72h (XTT assay); B) Cell growth curve after treatment with the drug;  C) DTCM-g inhibited the 
clonogenic capacity of both cell lines; D) DTCM-g treatments inhibited in vitro 5637 and T24 cell migration. Images were taken 
immediately and at 24 hours after wounding, in the absence (control) and presence of drug, as indicated. * Statistically different p<0.05.
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Cell irradiation
 To test the effect of DTCM-g on radioresistance a 
proliferation-based assay (XTT assay) was used, which 
is highly comparable to the clonogenic assay when the 
cells are allowed to undergo 6 cell divisions (Pauwels et 
al., 2003). Cell cultures were irradiated with γ-rays from 
60Cobalt at a dose rate of about 0.48Gy/min, using a 
Gammatron S-80 equipment (Siemens Medical Systems 
Inc., Iselin, NJ, USA) at the University Clinical Hospital 
(FMRP-USP). After irradiation with 2 and 4 Gy, the 
cells were plated in 96-well plates (100 microliters cell 
suspension, 500 cells/well) and the number of living cells 
was determined after 7 days by the proliferation XTT assay 
as described above. 
 The radiation dose enhancement ratio (DER) by 
DTCM-g was calculated using the following formula: 
DER = (surviving fraction at an indicated dose of radiation 
alone)/(surviving fraction at an indicated dose of radiation 
+ DTCM-g). Dose enhancement ratio=1 suggests an 
additive radiation effect and DER>1, a supra-additive 
effect as against a sub-additive effect in the case of DER<1 
(Tao et al., 2007).
Statistical analysis
 Statistical analyses were performed by using the 
SigmaStat software (Jandel Scientific Company, San 
Rafael, CA, USA).  One Way Repeated Measures Analysis 
of Variance (ANOVA) followed by the Holm-Sidak 
Pairwise Multiple Comparison was used to establish 
whether significant differences existed between groups. 
All tests were carried out for α = 0.05.
Results 
DTCM-g impairs cell proliferation in vitro
 DTCM-g effectively reduced the growth of 5637 cells 
after 48h at 20 µg/ml (p<0.05) when compared to control 
(DMSO 0.1%). Similarly, T24 cells showed significant 
growth reduction after 48h for DTCM-g 10 and 20 µg/
ml. IC50 values were determined as 14.29 and 10.06 µg/
ml for 5637 and T24, respectively, after 48hs of treatment. 
After 72h, both cell lines presented reduced growth at 
all concentrations tested (p<0.05) (Figure 1A), reducing 
the amount of living cells in the cultures by 47 and 53% 
for 5637 and T24, respectively (Figure 1A). Cell growth 
monitored at selected intervals by trypan blue exclusion 
showed a marked reduction of viable cells (Figure 1B). 
DTCM-g reduces the clonogenic capacity of T24 cells
 DTCM-g significantly reduced the colony formation 
capacity of the 5637 cell line at all concentrations tested 
when compared to control (p<0.05), reducing 68% of 
María S Brassesco et al
Asian Pacific Journal of Cancer Prevention, Vol 13, 20121960
clonogenicity at the highest concentration. Similarly, the 
clonogenic capacity of T24 cell line was reduced in 29 
and 63% at the 10 and 20 µg/ml treatments, respectively 
(Figure 1C). 
DTCM-g induces cell cycle arrest but not cell death in 
bladder carcinoma cell lines 
 Treatment of the cells with DTCM-g induced a 
sustained change in the cell cycle distribution at all times 
tested. During each period, treated cells significantly 
accumulated in the G1 phase. The percentage of the cells 
in S and G2 phases decreased accordingly as a result of 
treatment while untreated cells (control) were more evenly 
distributed throughout the cell cycle (Table 1). 
 On the other hand, the analysis of cells treated with 
DTCM-g through caspase-3 activation showed no effect 
on apoptosis in this assay, while flow cytometry analysis 
failed to detect increased acidic vesicular organelles 
through AO staining. Comparatively, the microscopical 
analysis of treated cells by differential staining with 
propidium iodide was also unable to demonstrate higher 
frequency of necrotic-like cells for both cell lines, 
suggesting that reduced cell numbers in vitro result from 
impaired proliferation rather than cell death (data not 
shown).
DTCM-g inhibits cell migration
 DTCM-g significantly reduced 5637 cell migration 
as measured by in vitro wound healing assays at 10 µg/
ml (p<0.05). For T24 cells, migration was significantly 
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Table 1. Cell Cycle Analysis of Bladder Carcinoma Cell Lines Treated with DTCM-g. Percentages of Cells in 
G1, S, and G2/M Phases are Expressed as Mean ± Standard Deviation of Triplicates.
                                                  5637                                        T24 
                                       24h                 48h           72h           24h       48h                 72h
Control  44.92 ± 1.38 54.30 ± 2.61 52.98 ± 3.16 43.82 ± 2.60 45.33 ± 1.45 48.56 ± 1.07
G1 (%): 2.5 µg/ml 46.21 ± 1.22 56.79 ± 2.72 60.34 ± 4.71 50.62 ± 4.38 47.37 ± 1.23 51.41 ± 2.09
 5 µg/ml 48.55 ± 2.32 58.82 ± 2.72 60.12 ± 6.44 50.95 ± 1.94 47.21 ± 1.82 47.57 ± 0.88
 10 µg/ml 54.08 ± 2.56 57.65 ± 0.83 61.88 ± 0.76 57.87 ± 1.58 49.96 ± 5.08 45.90 ± 1.61
 20 µg/ml 64.36 ± 2.04 64.32 ± 0.45 58.21 ± 2.16 46.36 ± 4.52 39.36 ± 6.28 30.79 ± 0.59
Control  15.52 ± 2.73 14.27 ± 1.86 14.75 ± 4.65 17.08 ± 1.81 15.74 ± 1.29 15.13 ± 2.05
S (%): 2.5 µg/ml 13.65 ± 1.07 14.30 ± 0.75 13.47 ± 2.68 16.14 ± 0.11 17.62 ± 0.96 13.80 ± 0.91
 5 µg/ml 15.44 ± 1.90 12.27 ± 3.75 8.99 ± 0.15 12.44 ± 1.25 15.31 ± 1.53 15.17 ± 1.32
 10 µg/ml  15.28 ± 1.12 14.47 ± 0.62 10.28 ± 1.36 9.72 ± 0.55 15.84 ± 2.68 14.31 ± 0.96
 20 µg/ml 8.76 ± 0.41 10.49 ± 0.66 9.86 ± 1.19 7.66 ± 1.52 12.60 ± 2.63 8.14 ± 1.79
Control  39.48 ± 1.04 30.13 ± 0.63 30.11 ± 3.40 23.18 ± 1.51 27.90 ± 3.23 24.28 ± 1.73
G2/M (%): 2.5 µg/ml 38.57 ± 2.26 28.76 ± 1.88 25.82 ± 4.94 24.70 ± 2.45 27.07 ± 1.79 22.39 ± 1.14
 5 µg/ml 34.49 ± 0.88 28.44 ± 5.28 29.51 ± 4.52 22.30 ± 1.38 28.81 ± 1.51 21.16 ± 0.72
 10 µg/ml 29.04 ± 1.90 27.17 ± 0.68 27.21 ± 1.22 19.30 ± 2.49 23.52 ± 6.50 19.23 ± 1.41
 20 µg/ml 14.01 ± 2.93 22.00 ± 0.65 28.29 ± 3.32 13.74 ± 0.58 18.23 ± 1.09 14.07 ± 2.70
Table 2. Radiosensitization Induced by DTCM-g on 
5637 and T24 Cell Lines. Cells were Pre-Treated with 
10 µg/ml for 24h and Irradiated with 2 and 4 Gy. After 
7 days Survival Fractions were Calculated
                                                  Cell line 
                                 5637                   T24
 2 Gy 1.00 1.25
 4 Gy 1.12 1.21
*DER = dose enhancement rate,  DER=1 and DER>1 indicate 
additive and supra-additive effects, respectively
inhibited after treatment with 2.5 and 10 µg/ml (Figure. 
1D).
DTCM-g pre-treatment sensitizes cells to ionizing 
radiation
 To study the cytotoxic effects of DTCM-g in association 
with γ-radiation, 5637 and T24 cells were incubated with 
10 µg/ml of the drug for 24h. After treatment, the cell 
culture medium was replaced and cells irradiated with final 
doses of 2 and 4 Gy. The results showed that DTCM-g pre-
treatment led to radiosensitization in both human bladder 
carcinoma cell lines at both doses tested (Table 2). 
 
Discussion
Over the past 30 years, systemic chemotherapy 
combining methotrexate, vinblastine, doxorubicin, 
and cisplatin (MVAC) has been the standard treatment 
option for patients with advanced or metastatic urothelial 
carcinoma. Nonetheless, a substantial proportion of 
patients relapse within the first year with a median survival 
of 12 months (Kaufman, 2006). Moreover, MVAC has 
shown to have significant toxicities including severe 
granulocytopenia, vomiting, and diarrhea (De Santis et 
al., 2009) and despite less toxic alternative treatment 
strategies, such as combinations of gemcitabine and 
cisplatin, the outcomes have not improved to any great 
extent. More recently, targeted therapies against metastatic 
or recurred urothelial carcinoma have emerged, mostly in 
the context of pre-clinical or phase I-II studies. Several 
molecular models directed to angiogenesis regulation 
and histone deacetylation are under study, some with 
promising results (Ismaelii et al., 2011).
The irregular activation of the PI3K /Akt ⁄ mTOR 
pathway has been involved in the oncogenesis of many 
tumors, including urothelial carcinoma (Qian et al., 2009). 
Several lines of evidence point to this pathway as an 
attractive target for cancer chemotherapy, mainly because 
it is relatively inactive in resting cells and it includes 
several upstream molecules (such as Ras and PI3K itself) 
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as well as many downstream targets of PI3K that can be 
aimed, including Akt and PDK1, among others (Sellers et 
al., 1999). Accordingly, in recent years, great interest in 
the search for small-molecule inhibitors that specifically 
inhibit key components of this pathway has emerged 
(Andersen et al., 2010). Several of these compounds 
show promising preclinical antitumor effects, and a few 
of them are currently undergoing clinical development 
(Peifer et al., 2009). Remarkably, much interest has been 
focused on PDK1. Only one single isoform of this protein 
has been so far reported in humans (Duronio, 2008), and 
unlike inhibitors of other members of the pathway, PDK1 
inhibitors may reduce the activity of a large number of 
other growth-promoting kinases including Akt, S6K, SGK, 
PKC and RSK (Peifer et al., 2009).
In the present study, we demonstrate the antiproliferative 
effects of DTCM-g, a novel PDK1 inhibitor on two 
bladder carcinoma cell lines, 5637 and T24. Our results 
showed that DTCM-g significantly decreased cell 
proliferation, inducing G1 arrest. The half-maximal 
effective concentration at 48h was determined as 14.29 and 
10.06 µg/ml for 5637 and T24 respectively, demonstrating 
DTCM-g effective action at low concentrations.
The potential anti-cancer effects of inhibiting the PDK1 
have been previously assessed in other models. Sato et al., 
(2002) proved potent anti-tumor activity of the PDK1 
inhibitor UCN-01 in murine colon adenocarcinoma NL-
17 cells. Also, the inhibition of PDK1 by phenothiazines 
resulted in suppression of EGF-induced cell growth in 
ovary cancer cells and inhibited growth in other several 
cancer cell lines, including melanoma (SK-MEL-28), 
colon (HT29, Colo205, SW480, HCT116) and breast 
cancer (MCF7) (Choi et al., 2008). Likewise, the inhibitor 
OSU03012 had profound effects on medulloblastoma 
(Baryawno et al., 2010) and neuroblastoma survival in 
vitro and in vivo (Segerstrom et al., 2011). The PDK1 
inhibitors, BX-795, BX-912, and BX-320 have also shown 
to inhibit growth in a wide panel of cell lines (Feldman 
et al., 2005). 
Regarding bladder carcinoma, Hansel et al., (2010) 
demonstrated reduced cell proliferation when mTOR (a 
downstream target) was inhibited by rapamycin in RT4, 
T24, J82 and UMUC3 cell lines. Also in support of the 
in vitro data, treatment of mice bearing subcutaneous 
T24 xenografts resulted in a 55% reduction in tumor 
size. However, although T24 cells exhibit constitutive 
activation of the PI-3 kinase pathway (Wu et al., 2004), 
Hansel and co-worlkers (Hansel et al., 2010) were also 
unable to detect any apoptosis. Combinations of caspase-
dependent and -independent mechanisms of cell death 
have been reported by others after PDK1 inhibition. 
While phenothiazines induced apoptosis in human ovary 
cancer cells (Choi et al., 2008), the PDK1 inhibitor 
OSU03012 induced mitochondrial dependent apoptosis of 
medulloblastoma cells (Baryawno et al., 2010), but was 
also reported to induce autophagy through accumulation 
of reactive oxygen species in hepatocellular carcinoma 
(Sargeant et al., 2007). In the present study, cytometric 
analysis after AO staining failed to detect increased 
autophagy in cells treated with DTCM-g. Also, we were 
unable to detect any necrosis after treating cells with this 
drug, suggesting that reduced cell numbers may result of 
impaired proliferation rather than cell death. On the other 
hand, flow cytometry analysis demonstrated sustained 
G1 arrest in 5637 and T24 cells after treatment with 
DTCM-g. Similarly, the dual PI3 kinase/mTOR inhibitor 
PI-103 induced a G1 arrest but no apoptosis in glioma 
(Fan et al., 2006) and G1 arrest with only minor apoptosis 
in neuroblastoma cells treated with the same inhibitor 
(Segerstrom et al., 2011).
Treatment with DTCM-g also demonstrated to sensitize 
5637 and T24 cells to ionizing radiation. Although 
combined chemotherapy with radiation for the treatment 
of advanced bladder cancer still remains questionable, 
a recent study by Ikeda et al. (2011) demonstrated that 
radiotherapy in combination with MVAC offers a survival 
benefit, particularly in locally advanced or metastatic 
bladder cancers. Moreover, radiotherapy can be indicated 
for unresectable tumors, or in inoperable patients, when 
combination with chemotherapy is not possible (Marta 
et al., 2012). Previous reports have demonstrated the 
radiosensitizing effects of inhibiting the PI3/Akt pathway 
in human bladder carcinoma T24 cells (Kim et al., 2005). 
Regarding PDK1, our findings are in accord with those of 
Gupta et al. (2003) who showed that its inactivation by 
LY294002 resulted in significant and synergistic reduction 
in clonogenicity and growth delay in xenografted T24 cells 
when combined with radiation. 
On the other hand, PI3/Akt pathway has demonstrated 
to be a critical downstream mediator of motility regulating 
invasion (Rieger-Christ et al., 2004). In the present study 
inhibition of PDK1 by DTCM-g significantly reduced 
migration as measured by in vitro wound healing assays 
in both aggressive bladder carcinoma cell lines, a relevant 
correlate to depth of invasion in human specimens. 
Similar results were obtained by Liu et al., (2009) who 
showed that small interference RNA markedly inhibited 
spontaneous migration and experimental metastasis of 
human breast cancer cells. Specially, Wu et al. (2004) 
also showed strong inhibition of invasion by the highly 
aggressive bladder tumor cell lines T24, J82 and UM-UC-
3v treated with the PDK1 inhibitor LY294002.
Hence, even though more studies are needed to 
corroborate our findings, our results indicate that directing 
against PDK1 through DTCM-g treatment could be 
useful to prevent cancer progression and abnormal tissue 
dissemination of advanced bladder carcinoma.
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